SCHEMBL12413729

SCHEMBL12413729

CC(C)CC(=O)N1CCCC1CN1CCCC1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 4/20 0.49
KCNH2 Q12809 2/20 0.47
OPRK1 P41145 4/20 0.46
OPRD1 P41143 2/20 0.46
NPC1 O15118 1/20 0.46
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2D6 P10635 1/20 0.46
CYP2C9 P11712 1/20 0.46
NFKB1 P19838 1/20 0.46
CYP2C19 P33261 1/20 0.46
HIF1A Q16665 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
BLM P54132 1/20 0.45
PMP22 Q01453 1/20 0.45
DRD4 P21917 1/20 0.45
SLC6A3 Q01959 1/20 0.45
TMEM97 Q5BJF2 1/20 0.45
SIGMAR1 Q99720 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12414850 1.00 HRH3 (0.49) HRH3KCNH2OPRK1OPRD1NPC1
SCHEMBL12414851 1.00 HRH3 (0.49) HRH3KCNH2OPRK1OPRD1NPC1
SCHEMBL12413722 0.97 OPRK1 (0.49) HRH3OPRK1OPRD1NPC1CYP1A2
SCHEMBL12413718 0.95 HRH3 (0.51) HRH3OPRK1OPRD1NPC1CYP1A2
SCHEMBL14557854 0.87 ITGB1 (0.47) HRH3KCNH2TDP1
SCHEMBL12413740 0.87 UTS2R (0.47) HRH3OPRK1OPRD1NPC1CYP1A2
SCHEMBL19432460 0.82 SMN1; SMN2 (0.49) NPC1
SCHEMBL12847184 0.82 HRH3 (0.52) HRH3KCNH2OPRK1OPRD1NPC1
SCHEMBL7539826 0.82 POLB (0.59) PMP22
SCHEMBL9675542 0.82 POLB (0.59) PMP22

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8293729-B2 Compounds, pharmaceutical composition and methods relating thereto BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-10-23 US disclosed
US-8293729-B2 Compounds, pharmaceutical composition and methods relating thereto BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-10-23 US disclosed
US-20110166116-A1 NEW COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS RELATING THERETO BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-07-07 US disclosed
US-20110166116-A1 NEW COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS RELATING THERETO BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-07-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110166116-A1 NEW COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS RELATING THERETO MC2R, REN, CYP11B2 HRH3 642/4885KCNH2 2188/4885OPRK1 1016/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.